NEJM: Hydroxychloroquine or hydroxychloroquine combined with azithromycin to treat new coronary pneumonia is not significant

Although there are clinical cases of hydroxychloroquine and azithromycin being used in the treatment of patients with Coronary Virus Disease (Covid-19) in 2019, there is limited evidence of the safety and effectiveness of this treatment.
Recently, researchers conducted a multi-center, randomized, open-label, three-group, controlled trial involving suspected or confirmed Covid-19 hospitalized patients who did not take oxygen or took less than 4 liters of oxygen per minute, and randomly received placebo, 400 mg of hydroxychloroquine, twice a day or 400 mg of oxycodone, twice a day in combination with 500 mg of azithromycin, for a total of 7 days.
result of the study was a 15-day clinical status assessed on a 7-level sequential scale (1-7, the higher the score indicates a serious illness).
667 patients were involved in the study, 504 of whom were diagnosed with Covid-19.
compared to standard care, there was no significant difference in the proportion of patients who scored higher on the 15th day of the serotonin (OR=1.21) and hydroxychloroquine plus azithromycin (OR=0.99) group 7 sequential scale assessment scores.
patients who were treated with hydroxychloroquine or hydroxychloroquine combined with azithromycin, the incidence of extended QT interstate and elevated heparin levels was higher than in placebo.
the study found that for patients hospitalized with mild and moderate Covid-19, the combination of hydroxychloroquine or hydroxychloroquine with azithromycin did not improve the clinical status of patients within 15 days, and the results did not support the combination of hydroxychloroquine or hydroxychloroquine and azithromycin in the treatment of neocycline pneumonia.